Limitations, agreements, and source contact

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) · Source last updated 2019-11-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

point Of Contact

email

UCBCares@ucb.com

organization

Cares

phone

+1844 599

phone Ext

2273

title

UCB

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice